Main Menu
- Home
- Symposium Videos
- Congress of Clinical Rheumatology
- CCR 2023 - East
- Welcome and Announcements - Dr. David McLain
- What is the Right Target in RA and PSA? - Daniel Aletaha, M.D., MSc, MBA
- Comparison of New Therapies for SLE - Michele Petri, M.D., M.P.H.
- Psoriatic Arthritis: Newest Approaches to Therapy? - Arthur Kavanaugh, M.D.
- Hurdles on the way to Disease modification of Lupus: LLDAS and Remission - Michele Petri, M.D., M.P.H.
- ANCA-Associated Vasculitis - John Stone, M.D., M.P.H.
- Biosimilars: How Similar Are They? - Jonathan Kay, M.D.
- Update on Sarcoidosis - Nadera Sweiss, M.D.
- CCR Thieves Market - Alan Epstein, M.D.
- Cutaneous Manifestations of Rheumatologic Disease - Alisa Femia, M.D.
- Choosing the Right Treatment for ARthritis: Efficacy, Safety, Context, and Preference - Daniel Aletaha, M.D., MSc, MBA
- IgG4-Related Disease - John Stone, M.D., M.P.H.
- Common Mimics in Derm-Rheum - Alisa Femia, M.D.
- Pulmonary Hypertension in Systemic Sclerosis - Virginia Steen, M.D.
- Systemic Sclerosis Associated Interstitial Lung Disease - Laura Hummers, M.D., Sc. M.
- Sjogren’s Disease Cluster Subtypes: What are They and Are they Useful to Predict Treatment, End Organ or Laboratory Abnormalities? - Sara McCoy, M.D., Ph.D.
- Ankylosing Spondylitis: How Has Current Understanding of Immunopathogenesis Led to Effective Therapeutic Targets? - Joerg Ermann, M.D.
- Current and New Targets for Treating Myositis - Julie Paik, M.D., M.H.P.
- Extra-Mucosal Manifestations, Comorbidities and Treatment of Sjogren’s in 2023 - Sara McCoy, M.D., Ph.D.
- The Epidemic Long COVID: Questions Implications for Rheumatology - Leonard Calabrese, D.O.
- Therapeutic Use of Cannabinoids in 2023 - Kevin Hill, M.D., MHS
- The History of Immunology: A Family Story - Leonard Calabrese, D.O.
- How Can Autoantibodies in Myositis Predict Prognosis? - Julie Paik, M.D., M.H.P.
- Current Concepts in the Care of Patients with Osteoporosis - Felicia Cosman, M.D.
- The Truth about CBD: Clinical Uses and Side Effects - Kevin Hill, M.D., MHS
- The Role of Osteoanabolic Agents in the Management of Patients with Osteoporosis - Felicia Cosman, M.D.
- CCR 2022 - West
- Rheumatoid Arthritis: How Early is Too Early to Diagnose and Treat? - John J. Cush, M.D.
- Update on Psoriatic Arthritis - M. Elaine Husni, M.D., MPH
- How Do the New Drugs Fit into the Current Treatment of SLE? - Richard Furie, M.D
- ANCA-Associated Cognitive Dysfunction in Rheumatic Diseases - Noa Schwartz, M.D., MS
- Rheumatology Year in Review 2022 - John Cush, M.D.
- Vasculitis Update - Kenneth J. Warrington, M.D.
- Role of the Rheumatologist in COVID - Leonard Calabrese, D.O.
- Serum Biomarkers of Disease Activity in Vasculitis - Kenneth J. Warrington, M.D.
- Antiphospholipid Syndrome: Overcoming Treatment Challenges - Richard Furie, M.D.
- Osteoarthritis: What’s New in 2022? - Anne-Marie Malfait, M.D., Ph.D.
- Update on the Pathogenesis and Treatment of Systemic Sclerosis - Elizabeth Volkmann, M.D., MS
- Spondyloarthritis 2022 - Atul Deodhar, M.D., MRCP
- Ehlers-Danlos Syndromes: More than Hypermobility - Anne-Marie Malfait, M.D., Ph.D.
- CCR Thieves' Market - Alan Epstein, M.D.
- What’s New in Inclusion Body Myositis - Thomas Lloyd, M.D., Ph.D.
- The Role of the Rheumatologist in the Early Diagnosis of Pulmonary Arterial Hypertension in CTD Patients - Sonja Bartolome, M.D.
- Treatment of Interstitial Lung Disease in 2022 - Elizabeth Volkmann, M.D., MS
- Skin Manifestations of Rheumatic Disease - Joseph Merola, M.D.
- The Utility of Autoantibodies in Determining Myopathy/Myositis - Thomas Lloyd, M.D, Ph.D.
- Dermatology for the Rheumatologist - Joseph Merola, M.D.
- When is Osteopenia Osteoporosis? - E. Michael Liewecki, M.D
- Shortcomings of the American Healthcare System - William E. Flanary, M.D
- Management of Chronic Pain: Empathy is not Equal to Sympathy - Kevin Zacharoff, M.D.
- Geriatric Rheumatology - Devyani Misra, M.D., MSc
- Navigating Regulatory Waters in Pain Management - Kevin Zacharoff, M.D.
- Sequential Therapy in Osteoporosis: When Does the Order Matter? - E. Michael Liewecki, M.D
- CCR 2022 - East
- COVID-19 for the Rheumatologist: Latest Advances in Science and Care - Leonard Calabrese, D.O.
- Psoriatic Arthritis: What's New in 2022? - Arthur Kavanaugh, M.D.
- Treatment Strategies for the Unresponsive Rheumatoid Arthritis Patient - Janet Pope, M.D., MPH, FRCP
- Cardiovascular disease in SLE: Who is at Risk and How Can We Prevent It? - Elisabet Svenungsson, M.D., PhD
- Hot Topics in Rheumatoid Arthritis - Arthur Kavanaugh, M.D.
- Vasculitis: Pearls for Practice - Philip Seo, M.D., MHS
- Pearls and Perils in the Diagnosis of Sjogren’s - Frederick B. Vivino, M.D., MS
- Giant Cell Arteritis: The Advanced Course - Philip Seo, M.D., MHS
- Autoantibodies in SLE: Can they Predict Disease Characteristics, Outcomes and Treatment Needs? - Elisabet Svenungsson, M.D., PhD
- Update on the Pathogenesis and Treatment of Systemic Sclerosis - Zsuzanna McMahan, M.D., MHS
- Sjogren Syndrome: Comprehensive Management - Frederick B Vivino, M.D., MS
- 2021 Year in Review: Clinical Pearls - Janet Pope, M.D., MPH, FRCP
- Evaluation and Management of GI Involvement in Scleroderma - Zsuzanna McMahan, M.D., MHS
- CCR Thieves` Market - Alan Epstein, M.D.
- What's new in IgG4 disease? - Zachary S. Wallace, M.D., MSc
- TBD - Jeffrey R. Curtis, M.D., M.S., M.P.H.
- Ankylosing Spondylitis: How Do Current & New Novel Therapeutic Targets Affect Radiographic Progression? - E. Nigil Haroon, M.D., PhD, DM
- What's New in Osteoporosis? - Michael McClung, M.D.
- Dermatology for the Rheumatologist 1: Cutaneous Lupus and Dermatomyositis - Avery H. LaChance, M.D., MPH
- CPPD: What have we learned, and where are we going? - Sara K. Tedeschi, M.D., M.P.H.
- Dermatology for the Rheumatologist 2: Fibrosis and Sclerosis - Avery LaChance, M.D., MPH
- Banquet - Rebalancing Pain Medicine: Improving Care Through a Wider Lens - Michael E. Schatman, Ph.D, CPE
- The Clinicoserological Spectrum of Inflammatory Myopathy in the Context of Systemic Rheumatic Diseases - Julie J. Paik, M.D., MHS
- MEDD Myth - Michael E. Schatman, Ph.D, CPE
- Can Autoantibody Profiles Predict Myositis Phenotype and Disease Course? - Julie J. Paik, M.D., MHS
- When and How to Sequence Osteoporosis Therapies - Michael McClung, M.D.
- CCR 2021 - West
- CCR 2021 - East
- CCR 2020 - West
- CCR 2020 - East
- CCR 2019 - West
- 2019 Update in Psoriatic Arthritis - Daphna D. Gladman, M.D., FRCPC
- Recent Changes in the Pathogenesis of Osteoarthritis - David Hunter, MBBS, M.Sc, MSpMed, PhD
- Hydroxychloroquine: Is it for every Lupus patient? - Michelle A. Petri, M.D., M.P.H.
- Autoinflammatory Syndromes - Peter A. Nigrovic, M.D.
- Treatment Updates in SLE - Michelle A. Petri, M.D., M.P.H.
- What Do We Really Know About Early RA? - Janet Pope, M.D.
- Intestinal Microbiome in Rheumatic Disease - Allen C. Steere, M.D.
- Update on the Management of Scleroderma, Including Raynaud's & Digital Ulcers - Dinesh Khanna, M.D., M.Sc.
- Update in the Therapy for Osteoarthritis - David Hunter, MBBS, M.Sc, MSpMed, PhD
- Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions - John G. Hanly, M.D., FRCP
- What's New in Gout in 2019? - Lawrence Edwards, M.D.
- Interstitial Lung Disease in Connective Tissue Disease - Dinesh Khanna, M.D., M.Sc.
- CCR Thieves' Market - Alan L. Epstein, M.D.
- Changing Trends in the Use of Opioids & Other Therapies for Arthritis Pain - Jeffrey R. Curtis, M.D., M.S., M.P.H.
- Vasculitis Mimics - Philip Seo, M.D., M.H.S.
- Update On Rheumatoid Arthritis - Jeffrey A. Sparks, M.D., M.M.Sc.
- ANCA-Associated Vasculitis - Philip Seo, M.D., M.H.S.
- Rheumatologic Manifestations Presenting From Checkpoint Inhibitors - Jeffrey A. Sparks, M.D., M.M.Sc.
- Pathogenesis, Evaluation and Treatment of the Patient with Myopathy: Are There Triggers? - Julie J Paik, M.D., M.H.S.
- Opioids in the Treatment of Non-Cancer Pain - Robert W. Hurley, M.D., Ph.D.
- Update on Osteoporosis 2019 - Nelson B. Watts, M.D., MACE, CCD
- Centralized Pain in the Rheumatologic Patient - Robert W. Hurley, M.D., Ph.D.
- Beyond Glucocorticoids. The Expanding List of Medications Associated with Osteoporosis: Does it Matter? What Should We Do About It? - Nelson B. Watts, M.D., MACE, CCD
- Is Myositis Always Myositis? - Julie J Paik, M.D., M.H.S.
- CCR 2019 - East
- Targets for Biologics in SLE - Ronald van Vollenhoven, M.D.
- Can We Prevent Rheumatoid Arthritis? - Paul Emery, M.D.
- Biomarkers in Systemic Lupus & Rheumatoid Arthritis - Ronald van Vollenhoven, M.D.
- What's New in Behçets Disease - Yusuf Yazici, M.D.
- What Should We Do For the Patient in Remission - Paul Emery, M.D.
- What's New in Ankylosing Spondylitis - Christopher Ritchlin, M.D., M.P.H.
- Comorbidity Conundrums & Therapeutic Controversies in Gout - Kenneth Saag, M.D., M.Sc
- Biomarkers in Connective Tissue Diseases - Judith James, M.D.
- Update in Safety Issues with Biologics & DMARDs - John Cush, M.D.
- What's New in Scleroderma - Fred Wigley, M.D.
- Difficult Scenarios in Biologic Use - John Cush, M.D.
- Update on Sjogren's Syndrome - Steve Carsons, M.D.
- Childhood Dermatomyositis Update - Brian Feldman, M.D.
- Update on Undifferentiated Connective Tissue Disease - Judith James, M.D.
- CCR Thieves' Market - Alan Epstein, M.D.
- Eye Disorders in Rheumatic Disease - James T Rosenbaum, M.D.
- What's New in Juvenile Inflammatory Arthritis? - Brian Feldman, M.D.
- Dermatologic Manifestations of Rheumatologic Disease, Part 1 - Joseph F. Merola, M.D., M.Sc.
- New Treatments in Psoriatic Arthritis - Philip Mease, M.D.
- Dermatologic Manifestations of Rheumatologic Disease, Part 2 - Joseph F. Merola, M.D., M.Sc.
- Pain in the Opioid Odyssey - Lynn R Webster, M.D.
- Individualization of Osteoporsis Treatment in 2019 - Michael McClung, M.D.
- Controversies in Osteoporosis Treatment - Michael Lewiecki, M.D.
- Osteoporosis Challenging Cases - Michael McClung, M.D.
- Small Fiber Neuropathy & Chronic Pain: Implications for Rheumatology - Charles Argoff, M.D.
- CCR 2018
- Novel Therapeutic Strategies in Rheumatoid Arthritis - Gerd R. Burmester, M.D.
- New Insights into the Pathogenesis & Clinical Features of SLE - Michelle A. Petri, M.D., M.P.H.
- The Future of Rheumatology: Rheumatology 4.0? - Gerd R. Burmester, M.D.
- Recent Advances in the Pathogenesis & New Targets in the Treatment of Systemic Vasculitis - Christian Pagnoux, M.D., M.Sc., Ph.D.
- What's New in Sarcoid? - Daniel A. Culver, D.O.
- Management of Systemic Sclerosis: Navigating Recommendations and Guidelines - Janet E. Pope, M.D.. M.P.H.
- Interstitial Lung Disease in Connective Tissue Disease: Existing and Emerging Therapies - Elizabeth R. Volkmann, M.D., M.S.
- Update in the Remission Rate and Treatment of Lupus - Michelle A. Petri, M.D., M.P.H.
- ANCA Associated Vasculitis: New Concepts in Treatment - Christian Pagnoux, M.D., M.Sc., Ph.D.
- Scleroderma & Intestinal Microbiome: Is There an Association? - Elizabeth R. Volkmann, M.D., M.S.
- Update in IgG 4 Related Disease - Arezou Khosroshahi, M.D.
- Cancer, Immunotherapy & Autoimmune Syndromes - Ami A. Shah, M.D.
- CCR Thieves’ Market - Alan Epstein, M.D.
- Treatment of Chronic Pain in the Opioid Epidemic - Katherine E. Galluzzi, D.O., CMD
- Microglia: New Targets in the Treatment of Fibromyalgia - Jarred W. Younger, Ph.D.
- NewTargets in theTreatment of Psoriatic Arthritis: How do They Change our Management? - Arthur F. Kavanaugh, M.D.
- Evidence-based Guidelines for Optimal Gout Management - Hyon-Kyoo Choi, M.D., Dr.PH
- Spondyloarthrits: Update on Pathogenesis, Diagnosis & Management - Arthur F. Kavanaugh, M.D.
- Medical Marijuana - Kevin P. Hill, M.D., M.H.S.
- Overview of New Anabolic Treatments - Felicia Cosman, M.D.
- Monitoring Osteoporosis Treatment - Paul D. Miller, M.D.
- Optimal Treatment Stratgegies for High Risk Patients - Felicia Cosman, M.D.
- Evaluating Long-Term Osteoporosis Therapies: Balancing the Benefits and Risks - Paul D. Miller, M.D.
- Connective Tissue Disease Biomarkers and Serologic Testing for 2018 - Maureen Mayes, M.D. and John Goldman, M.D.
- CCR 2017
- Pathogenesis and Treatment of Rheumatoid Arthritis in 2020? - Iain McInnis, M.D., Ph.D, FRCP, FRSE, FMedSci
- Current Therapeutic Strategies in Rheumatoid Arthritis - Edward Keystone, M.D., FRCP (C)
- Updates in Treatment of Psoriatic Arthritis - Iain McInnis, M.D., Ph.D, FRCP, FRSE, FMedSci
- New Treatments in RA - Mark C. Genovese, M.D.
- Pseudogout: Update on Treatment and Associated Co-Morbidities - Ann K. Rosenthal, M.D.
- Improving RA Outcomes in the Future - Mark C. Genovese, M.D.
- Glucocorticoid-Induced Osteoporosis: Where do new treatments fit in the old guidelines? - Kenneth S. Saag, M.D., M.Sc.
- New & Emerging Therapies for Systemic Lupus Erythematosus - Richard Alan Furie, M.D.
- Adverse Drug Reactions With Biologics & New Therapies - John J. Cush, M.D.
- Interstitial Lung Disease in Connective Tissue Disease - Aryeh Fischer, M.D.
- Difficult to Treat RA and RA Pearls - John J. Cush, M.D.
- Advances in the Treatment of Giant Cell Arteritis - Robert F. Spiera, M.D.
- Pregnancy and Medications During Pregnancy in Rheumatic Disease Patients - Lisa R. Sammaritano, M.D.
- Update on Treatments in Scleroderma - Robert F. Spiera, M.D.
- Peri-operative Management for Patients with Rheumatic Diseases - Susan M. Goodman, M.D.
- CCR Thieves Market - Alan L. Epstein, M.D.
- Pain - Dynamics and Complexities - Daniel M. Doleys, Ph.D.
- Update on ANCA-Associated Vasculitis - Carol A. Langford, M.D., M.H.S.
- Evaluation of Patients With Myopathy - Lisa Christopher-Stine, M.D., M.P.H.
- Gout & Osteoarthritis: Associations, Pathophysiology, and Therapeutic Implications - Svetlana Krasnokutsky, M.D., M.S.
- Skin Manifestations of Rheumatic Disease - Drew J. Kurtzman, M.D.
- MACRA & MIPS: What do they mean to our practice & how do we comply? - William F. Harvey, M.D., M.Sc.
- Prescription Abuse from a DEA Perspective - Richard A. Tucker
- Statin-Induced Myopathy - Lisa Christopher-Stine, M.D., M.P.H.
- Dermatology Pearls for the Rheumatologist - Drew J. Kurtzman, M.D.
- Update on Sjogrens - Fredrick B. Vivino, M.D., M.S.
- Update on Gout - N. Lawrence Edwards, M.D.
- CCR 2016
- New Advances in Undifferentiated Connective Tissue Disease and Incomplete LupusErythematosus - Judith James, MD, PhD
- Management of RA: Targets and Options - Daniel Aletaha, MD, MSc
- Lupus Management after failure of First line treatment - Janet Pope, MD, MPH
- New Insights into CNS Lupus - Meggan Mackay, MD, MS
- Serology in RA: Clinical and therapeutic implications - Daniel Aletaha, MD, MSc
- Treatment Advances in Scleroderma - Fred Wigley, MD
- Scleroderma Overlap Syndromes - Janet Pope, MD, MPH
- Raynaud’s phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management - Fred Wigley, MD
- Current Issues with Osteoporosis Treatment - Nelson Watts, MD, FACP, MACE
- Targeting Extra-Articular Manifestations in PsA: A Closer Look at Enthesitis and Dactylitis - Christopher Ritchlin, MD, MPH
- New and Emerging therapies: how could they change our current guidelines of osteoporosis treatment - Michael McClung, MD
- How Immunologic Advances Have Revealed New Targets in PsO and PsA - Christopher Ritchlin, MD, MPH
- Disease Relapses and treatments in Vasculitis - Gary Hoffman, MD, MS, MACR
- Behcet’s Update including new therapies - Kenneth Calamia, MD
- Evidence for a vascular microbiome and its role in vessel health and disease - Gary Hoffman, MD, MS, MACR
- Thieves’ Market - Alan Epstein, MD
- Management of Axial Spondyloarthritis - Robert Inman, MD
- The effect of RA therapies on the outcome of cardiovascular disease, insulin resistance and other co- morbidities - Joan Bathon, MD
- Gout and Metabolic Syndrome: What Is the Connection? - Michael Pillinger, MD
- Management of the Difficult-To-Treat Gout Patients - Robert Keenan, MD, MPH
- Biosimilars in Rheumatic Diseases: The Science and Policy Issues - Alan Epstein, MD
- Safety issues with Biologics - Jeffrey Curtis, M.D., MS, MPH
- Biological Basis of Osteoarthritis - Charles J. Malemud, PhD
- CCR 2015
- Emerging Treatments of RA - Edward Keystone, M.D.
- Pathogenesis and treatment of Rheumatoid Arthritis in 2020? - Iain McInnes, M.D., Ph.D.
- Treating to Target in Psoriatic Arthritis - Laura Coates, M.D.
- Reducing the Cost of Biologics: Dose Reduction, Withdrawal & Biosimilars - Edward Keystone, M.D.
- PsA – a new future opening up? - Iain McInnes, M.D., Ph.D.
- Update on ANCA-associated Vasculitis - Philip Seo, M.D., M.H.S.
- CTD associated Interstital Lung Disease - Kristin Highland, M.D.
- The Spectrum of Gout and Hyperuricemia: Acute Attacks to Refractory Chronic Gout - Joseph Grisanti, M.D.
- Clinical Update on Sarcoidosis - Kristin Highland, M.D.
- Glucocorticoids in Rheumatology: Clinical use, mechanisms of action - Frank Buttgereit, M.D.
- Sjogren’s Syndrome: Clinical Presentation and Outcome - Athanasios G. Tzioufas, M.D.
- Glucocorticoids in Rheumatology: Adverse effects and new developments - Frank Buttgereit, M.D.
- The Biomarker Odyssey in SLE: Practical or Esoteric - Susan Manzi, M.D., M.P.H.
- Lupus Pregnancy: Management and Outcome - Lisa Sammaritano, M.D.
- Sjogren’s Syndrome: Therapeutic modalities: Current status and future prospects - Athanasios G. Tzioufas, M.D.
- CCR Thieves Market - Alan Epstein, M.D.
- Diagnosis and Management of the Spondyloarthropathies (SpA)- Impact of Treat to Target Guidelines - Alan Epstein, M.D.
- Microglial Modulation in the Treatment of Fibromyalgia - Jarred Younger, Ph.D.
- New and Emerging Therapies in Osteoporosis - John Bilezikian, M.D.
- Rheumatic Manifestations of Endocrine Disease - Joseph Markenson, M.D.
- The Year in Review: Osteoporosis - John Bilezikian, M.D.
- Evaluation and Management of Systemic Lupus Erythematous, 2015 - Michelle Petri, M.D., M.P.H.
- Utilization of Viscosupplementation in the Treatment of Knee Osteoarthritis: Identifying Potential Patients - John Tesser, M.D.
- The Discovery of Cortisone - Thom W. Rooke, M.D.
- Adverse Drug Reactions and issues with newer therapies in RA - John J. Cush, M.D.
- Non-malignant Chronic Pain Management - Dan Doleys, Ph.D.
- Preventing Infections in patients on Biologics - John J. Cush, M.D.
- ICD-10 for Rheumatologists - Charles King, II, M.D.
- CCR 2014
- Behçet's Syndrome: Update 2014 - Yusuf Yazici, M.D.
- Lupus Update 2014 - Michele Petri, M.D., M.P.H.
- Scleroderma -- Evidence of a Vascular Disease - Fredrick Wigley, M.D.
- Infections and Autoimmunity -- How Can We Harness Nature to Treat Autoimmune Diseases? - Yehuda Shoenfeld, M.D., FRCP
- Vascular Treat to Target -- Possible Strategy in Scleroderma? - Fredrick Wigley, M.D.
- ASIA: Autoimmune/Autoinflammatory Syndrome - Induced by Adjuvants and Autoimmune Rheumatic Diesases, 2014 -- Yehuda Shoenfeld, M.D., FRCP
- Central Pain Mechanisms in the Rheumatic Diseases - Kristine Phillips, M.D., Ph.D.
- To D or Not to D? -- This is the question - Yehuda Shoenfeld, M.D., FRCP
- Antiphospholipid Antibody Syndrome Update - Michele Petri, M.D., M.P.H.
- Cryoglobulinemia - Peter Gorevic, M.D.
- Inclusion Body Myositis - Thomas Lloyd, M.D., Ph.D..
- CCR Thieves' Market - Alan Epstein, M.D., Moderator
- Joint Hypermobility Syndrome -- An Evolving Multi-System Disorder - Rodney Grahame, M.D., FRCP
- Gout Update - Robert Keenan, M.D., M.P.H.
- Management of the Joint Hypermobility Syndrome - Rodney Grahame, M.D., FRCP
- What's New in Spinal Osteoarthritis? - Alfred C. Gellhorn, M.D
- Inflammatory Eye Diseases in the Rheumatic Disease Patient - Robert Keenan, M.D., M.P.H.
- Disease Activity Measurement and Biomarkers in RA - Max Hamburger, M.D.
- Current Legislative & Regulatory Issues Facing Rheumatologists - Robert S. Jasak, J.D.
- Sequential/Combination Therapy in Osteoporosis - Felicia Cosman, M.D.
- Regulation of Bone Homeostasis: Signaling Pathways and Novel Targets - David W. Dempster, PhD, FRMS
- Treatment to Goal in Osteoporosis - Felicia Cosman, M.D.
- CCR 2013
- Estrogen metabolism and autoimmunity - Maurizio Cutolo, M.D.
- Pathogenesis of SLE - George Tsokos, M.D.
- What novel drugs do we need for the treatment of rheumatoid arthritis? - Steffen Gay, M.D.
- Raynaud's Phenomenon, Systemic Sclerosis And Capillaroscopy - Maurizio Cutolo, M.D.
- Mechanisms of Tissue Injury in SLE - George Tsokos, M.D.
- Epigenetics: The new kid on the block, Regulating our cells and mind - Steffen Gay, M.D.
- New developments in diagnosis and treatment of systemic vasulitis - Gary Hoffman, M.D., M.S.
- New Insights into Dermatomyositis - Brian Feldman, M.D., M.Sc., FRCPC
- Self-management and transitional care in Adolescents with JIA - Brian Feldman, M.D., M.Sc., FRCPC
- Aging and the Immune System? - Cornelia Weyand, M.D., Ph.D.
- New Therapies in SLE - Susan Manzi, M.D., M.P.H.
- Factors that influence organ targeting and disease patterns in systemic vasculitis - Gary Hoffman, M.D., M.S.
- Update on Giant Cell Arteritis - Cornelia Weyand, M.D., Ph.D.
- Neurological complications of Lupus and Sjogren's syndrome - Julius Birnbaum, M.D.
- CCR Thieves' Market - Joseph Grisanti, M.D., Moderator
- CSRO Update: Legislative and Regulatory Issues Facing Rheumatologists - Emily Graham, RHIA, CCS-P
- Therapeutic Trends with Biologics in RA - Edward Keystone, M.D.
- Safety of Biologics and new Non-Biologics in RA - John Cush, M.D.
- The Role of CNS amplification in Musculoskeletal Pain: Implications for Treatment and Rehabilitation - Daniel Clauw, M.D.
- Acute Pain to Chronic Pain Pathophysiology - Christopher Gharibo, M.D.
- Fibromyalgia Update - Daniel Clauw, M.D.
- Spondyloarthropathy Update - Alan Epstein, M.D.
- JFK's Pain Story; A Case of Disabling Autoimmune Disease - Forest Tennant, M.D.
- Individualizing Osteoporosis Therapy - Michael Lewiecki, M.D.
- Sarcopenia, Fat, and Fracture Risk - Neil Binkley, M.D.
- New and emerging treatments for osteoporosis - Michael Lewiecki, M.D.
- CCR 2012
- Bone & Cartilage: Prey of arthritis - Georg Schett, M.D.
- CSRO Update: Legislative and Regulatory Issues Facing Rheums - Emily L. Graham, RHIA, CCS-P
- News on Bone Erosion in Rheumatoid Arthritis - Georg Schett, M.D.
- Imaging the immune system in the future: more than meets the eye? - Iain McInnes, M.D., Ph.D.
- Mixed Connective Tissue Disease; Not so Mixed - Virginia Steen, M.D.
- Translating clinical questions into laboratory answers? - Iain McInnes, M.D., Ph.D.
- Treating Rheumatoid Arthritis to Target - Max Hamburger, M.D.
- Glucocorticoid-Induced Osteoporosis: A Translational Science Journey - Nancy Lane, M.D.
- Advancing the Management of Systemic Lupus Erythematosus - Michelle Petri, M.D., M.P.H.
- Psoriatic Arthritis Update - Philip Mease, M.D.
- Myopathies, 2012 - Robert Wortmann, M.D.
- ANCA-Associated Vasculitis: What do the results of the RAVE trial mean for the treatment of MY patient? - John Stone, M.D., M.P.H.
- Accelerated atherosclerosis in SLE: mechanisms and prevention approaches - Bevra Hahn, M.D.
- IgG4-Related Disease: A newly-recognized rheumatologic condition - John Stone, M.D., M.P.H.
- Update on ACR treatment guidelines for lupus nephritis, and future therapies - Bevra Hahn, M.D.
- Targeted Therapy of Systemic Sclerosis - Virginia Steen, M.D.
- Update on Interstitial Lung Disease - David Moller, M.D.
- CCR Thieves' Market - John Tesser, M.D., Moderator
- Update on the Recommendations for the Diagnosis and Management of Gout and Hyperuricemia - Allan Morton, D.O.
- Update on the Pathobiology and Treatment of Sarcoidosis - David Moller, M.D.
- Osteoarthritis Update - Nancy Lane, M.D.
- Low-dose naltrexone for the treatment of fibromyalgia: the role of microglia modulation in treating musculoskeletal pain - Jarred Younger, Ph.D.
- Update on Complementary and Alternative Medicine in Rheumatology - Sharon Kolasinski, M.D.
- Brain changes in the first month of daily opioid therapy: implications for addiction, hyperalgesia, and other adverse consequences - Jarred Younger, Ph.D.
- Rheumatic Manifestations of Cancer - David Daikh, M.D.
- Osteoporosis Screening: Estimating an Age to Start and a Screening Interval - Margaret L. Gourlay, MD, MPH
- Bisphosphonates: Safety and Effectiveness for Osteoporosis Treatment - Susan Ott, M.D.
- CCR 2011
- Extreme Clinic: An Outpatient Doctor's Guide to the Perfect 7 Minute Visit - Thomas Laurence, MD
- The IOM's New Guidlines for Vitamin D and Calcium Intake - JoAnn E Manson, MD, DrPH
- Celiac Disease and Rheumatology - Alexa B. Adams, MD
- The Roles of MRI in Arthritis - Clyde Helms, MD
- Predicting LongTerm Outcomes in RA - Edward C. Keystone, MD, FRCP(C)
- Recently Approved and Emerging Therapies For RA - Edward C. Keystone, MD, FRCP
- Cardiovascular Risk in RA - Joan Bathon, MD
- Update Behcets Disease in the USA - Kenneth Calamia MD, FACP
- The Significance of Comorbidities in Rheumatoid Arthritis - Alan L. Epstein, MD
- State of the Art of Treatment of Osteoporosis - Michael McClung, M.D., FACE, FACP
- Treatments in Development for Osteoporosis - Michael McClung, M.D., FACE, FACP
- Health Care Reform: Impact on Patients and Physicians - Michael Schweitz, MD
- Long Term Use of Bisphosphonates: Fact and Fiction - Nelson Watts, M.D.
- Gout, Uric Acid, and the Metabolic Syndrome - N. Lawrence Edwards, M.D.
- Pain and Aging - Perry Fine, M.D.
- Safe and Effective Opioid Rotation - Perry Fine, M.D.
- New Treatments for SLE - R. John Looney, MD
- Update on Sjogren's syndrome: from pathogeny to treatment - Xavier Mariette, M.D., Ph.D.
- Long term safety of TNF blockers - Xavier Mariette, M.D., Ph.D.
- Thieves' Market - Alan N. Brown, M.D.
- Vitamin D in the Prevention of Cancer and Cardiovascular Disease - JoAnn E Manson, MD, DrPH
- The Conundrum of Choices for the Treatment of RA - Joan Bathon, MD - Joan Bathon, MD
- CCR 2010
- (Almost) Everything You Need to Know About PQRI - Jean Acevedo, LHRM, CPC, CHC
- Antiphospholipid Antibody Syndrome - Graham Hughes, MD, FRCP
- B Cell Depletion in Lupus - Graham Hughes, MD, FRCP
- FRAX, WHO Fracture Risk Assessment Tool - Chad Deal, MD
- Interstitial Lung Disease in Systemic Sclerosis - Philip Clements, MD, MPH
- Medicate: What You Need To Know About Recovery Audit Contractors (RACs) - Mike Schweitz, MD, FACP, FACR
- New Therapeutic Targets in RA - Iaian McInnes, FRCP, PhD, FRSE
- RA Treatment and Malignancies - Tim Bongartz
- Treatment of Scleroderma, 2010 - Philip Clements, MD, MPH
- Update of Treatments in Development for Lupus - Joan T. Merril, MD
- Vascular Co Morbidity in Rheumatic Diseases - Iaian McInnes, FRCP, PhD, FRSE
- Options in Management of Mild-Moderate-Severe Lupus - Joan T. Merrill, MD
- CCR 2009
- ROB 2008
- The Lyme Disease Controversy - Allen C Steere, MD
- Antiphospholipid Antibody Syndrome - Robin L Brey MD
- A Potpourri of PTH - Paul D Miller MD
- A Revisionist View of Osteoporosis - Stavros C Manolagas MD PhD
- Emerging Therapeutic Targets for RA - Clifton O Bingham III, MD.
- Managing Comorbidities in RA - John J Cush, MD.
- Neuropsychiatric Lupus - Robin L Brey, MD
- Opioid - Jianren Mao, MD, PhD
- Osteoarthritis Update - Richard Loeser Jr., MD
- RA and Metabolic Syndrome - Charles Michael Stein, MD
- Safety of Biologics - John J Cush, MD
- Scleroderma is a Treatable Disease - James R Seibold, MD
- Short and LongTerm Safety of Bisphosphonates - Paul D Miller, MD
- SLE Treatment Update - Goldman, MD, DrPH, Rosalind Ramsey
- The Yin and Yang of Immunomodulation - Clifton O Bingham III, MD
- Update on Pediatric Systemic Lupus Erythematosus - Earl Silverman, MD, FRCP(C)
- Update on Vitamin D - Michael F Holick, PhD, MD
- Utility of Ultrasound in Rheumatology - Ralf Thiele, MD, FACR
- North American Young Rheumatology Investigator Forum
- NYRIF 2019
- Systemic Lupus Erythematosus Patients with Common Variable Immunodeficiency Disease - Hamdy Ahmed, M.D.
- Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Systemic Lupus Erythematosus- A Retrospective Study - Alisha Gupta, M.B.B.S., M.D.
- Missed Opportunity? Evaluation for Systemic Autoimmune Diseases in Patients with Uveitis may not be Optimal - Nancy Harrison, M.D.
- Is gout a risk factor for development of cancer? - Patricia Chan Kachur, M.D., MS
- Statin Therapy in Systemic Lupus Erythematosus (SLE) Patients Cross-sectional analysis of a large population database - Yael Klionsky, M.D.
- Causes and Predictors of 30day and 90day readmission rate for ANCA associated Vasculitis Insights from Nationwide Readmission Database - Mukund Kumar, M.D.
- A Distinct T Follicular Helper Cell Subset Infiltrated the Joints and Peripheral Blood in Experimental Inflammatory Arthritis and were Inhibited by a Small Molecule Inhibitor - Nitasha Kumar, M.D.
- Should Rheumatoid Factor and Anti-CCP Antibodies be Repeated in Patients with a Diagnosis of Seronegative Inflammatory Arthritis - Ricky Mehta, M.D.
- A New Tool to Assess Muscle Strength in Polymyositis and Dermatomyositis Hand held Dynamometry - Didem Saygin, M.D.
- Influenza and Pneumococcal vaccines in patients with Systemic Lupus Erythematosus - Findings From a Large Urban Public Hospital - Anam Umar, M.D.
- NYRIF 2019 Panel Discussion -
- NYRIF 2018
- NYRIF 2018 Intro - David McLain, M.D.
- Hypophosphatemia in the Setting of Metabolic Bone Disease - Lee Day, M.D.
- Treatment Algorithms for Systemic Sclerosis According to Experts - Andreu Fernandez Codina, M.D.
- Utility of Carotid Ultrasound Compared to Framingham Risk Score in Predicting Cardiovascular Mortality in Rheumatoid Arthritis - Pankhuri Gupta, M.D.
- Inpatient Cost Burden for Patients with Acute Myocardial Infarction and Underlying Psoriatic Arthritis - Shraddha Jatwani
- Losing Antiphospholipid Antibodies Post Thrombosis in Secondary APS - Muznay Khawaja, M.D.
- Statin Therapy in SLE Patients: Prevalence of Statin Use in a Large Population Database - Yael Klionsky, M.D.
- RGS Proteins as Mediators of Inflammation and Tissue Damage in a Mouse Model Systemic Lupus Erythematosus - Patrick Mastin, M.D.
- Depression Screening and Intervention in Rheumatoid Arthritis and Systemic Lupus Erythematosus - Rui Zhang, M.D., PhD
- Rheumatoid Arthritis is not an Independent Risk Factor for Mortality in End Stage Renal Disease - Sunita Paudyal, M.D.
- Mortality in Selected Rheumatologic Diseases Using the National Inpatient Sample from 2002-2014 - Rouhin Sen, M.D.
- Temporal Trends and mortality of Hospitalized Patients with Adult-Onset Stills Disease - Bella Y. Mehta
- NYRIF Faculty Panel - Multiple
- NYRIF 2016
- Introduction - Daniel Aletaha, M.D., MHS
- Exploring the Associations Between Air Pollutant Exposure and Rheumatoid Arthritis Seropositivity - Asah Alex, MD
- Genomic Sequencing of Uric Acid Metabolizing and Clearing Genes and Relationship to Xanthine Oxidase Inhibitor Dose - Jess Anderson
- Toxic and Inflammatory Myopathy in the Setting of Pembrolizumab - Prat eek Gandiga, MD, FACP
- Comparing Corticosteroid Preparation and Dose in Subacromial Bursitis: A Randomized, Single Blind Study - Spencer Motley
- Histone H2AX phosphorylation as a measure of DNA double strand breaks and a marker of environmental stress in lupus - Raja Namas, MD
- Can Exercise Echocardiography Predict Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients? - Kaitlin Quinn, MD
- Coagulation Pathway Function in Ischemia/Reperfusion Tissue Injury in Autoimmune Prone Mice - Rachel Robbins, MD
- Validation of the QuickDASH in the Assessment of Rheumatoid Arthritis Disease Activity - George Shahin, MD
- Common Viral Pathogens in Arthritis: A Population-Based Study - Anna Shmagel
- Distinguishing Features of Skin Manifestations in Monogenic Autoinflammatory Disorders - Kyawt Shwin
- Ultrasound of the Posterior Tibial Tendon and Peroneus Brevis Tendon - Ian Ward, MD
- NYRIF 2015
- NYRIF 2014
- NYRIF 2014 Introduction -
- Routine Assessment of Patient Index Data 3 Scores correlate well with Bath Ankylosing Spondylitis Disease Activity index in the Assessment of Disease Activity and Monitoring Progression of Ankylosing Spondylitis - Abhijeet Danve, M.D.
- Measurement Properties Of Multidimensional Health Assessment Questionaire in Lupus - Narender Annapureddy, M.D.
- A Unique Case of Isolated Carotid Artery Takayasu’s Arteritis - Melissa S. Butts, D.O.
- Thymic Stromal Lymphopoietin (TSLP) is Elevated in Patients with Systemic Lupus Erythematosus or Rheumatoid Arthritis - Marven Gerel Cabling, M.D.
- Deletion of RBP-J in a Murine Model of Inflammatory Arthritis Reveals Pro-Inflammatory Cytokine Expression and Immunophenotypic - Soumya Chakravarty, M.D.
- Relationship of a Xanthine Oxidase Single Nucleotide Polymorphism to Dose of Allopurinol - Amanda L. Deans, M.D.
- Pityriais rubra pilaris-associated polyarthritis: Impact on quality of life and potential prognostic implications. - A. Brooke W. Eastham, M.D.
- A novel murine model of B cell-mediated glomerular injury is mediated by cytokines - Alfred H. Kim, M.D., PhD
- Dynamics of the Inflammatory Response in Rheumatoid Arthritis patients following traumatic injury: Insights from in vivo,in silico, and Single Nucleotide Polymorphism studies. - Rajaie Ahmd Namas, M.D.
- The epidemiology of concomitant psoriasis and hidradenitis suppurativa: A retrospective analysis from an academic medical center - Mital Patel, M.D.
- Churg Strauss Syndrome Presenting as Acute Pain Syndrome with Myositis and Fascitiis After Rigorous Exercise - Seema Qaiyumi, M.D.
- Adalimumab induced Bullous Pyoderma Gangrenosum in a middle aged African American male – a rare complication - Thamilvani Thiruvasahar, M.D.
- Dysferlin: Clinical Enigma of Myopathy - Kenneth Van Dyke, DO
- Comparative Study of Patients with Psoriatic Arthritis (With and Without Axial Disease) with Axial Spondyloarthritis - Abhijeet Danve, M.D.
- NYRIF 2013
- Immunology for Rheumatology Providers
- Parkinson Association of Alabama
- Advances in Pain Care
- How It Works
- FAQ
- Login
